Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
MAFB shapes human monocyte–derived macrophage response to SARS-CoV-2 and controls severe COVID-19 biomarker expression
Miriam Simón-Fuentes, … , Ángel L. Corbí, Ángeles Domínguez-Soto
Miriam Simón-Fuentes, … , Ángel L. Corbí, Ángeles Domínguez-Soto
Published November 2, 2023
Citation Information: JCI Insight. 2023;8(24):e172862. https://doi.org/10.1172/jci.insight.172862.
View: Text | PDF
Research Article COVID-19 Immunology

MAFB shapes human monocyte–derived macrophage response to SARS-CoV-2 and controls severe COVID-19 biomarker expression

  • Text
  • PDF
Abstract

Monocyte-derived macrophages, the major source of pathogenic macrophages in COVID-19, are oppositely instructed by macrophage CSF (M-CSF) or granulocyte macrophage CSF (GM-CSF), which promote the generation of antiinflammatory/immunosuppressive MAFB+ (M-MØ) or proinflammatory macrophages (GM-MØ), respectively. The transcriptional profile of prevailing macrophage subsets in severe COVID-19 led us to hypothesize that MAFB shapes the transcriptome of pulmonary macrophages driving severe COVID-19 pathogenesis. We have now assessed the role of MAFB in the response of monocyte-derived macrophages to SARS-CoV-2 through genetic and pharmacological approaches, and we demonstrate that MAFB regulated the expression of the genes that define pulmonary pathogenic macrophages in severe COVID-19. Indeed, SARS-CoV-2 potentiated the expression of MAFB and MAFB-regulated genes in M-MØ and GM-MØ, where MAFB upregulated the expression of profibrotic and neutrophil-attracting factors. Thus, MAFB determines the transcriptome and functions of the monocyte-derived macrophage subsets that underlie pulmonary pathogenesis in severe COVID-19 and controls the expression of potentially useful biomarkers for COVID-19 severity.

Authors

Miriam Simón-Fuentes, Israel Ríos, Cristina Herrero, Fátima Lasala, Nuria Labiod, Joanna Luczkowiak, Emilia Roy-Vallejo, Sara Fernández de Córdoba-Oñate, Pablo Delgado-Wicke, Matilde Bustos, Elena Fernández-Ruiz, Maria Colmenares, Amaya Puig-Kröger, Rafael Delgado, Miguel A. Vega, Ángel L. Corbí, Ángeles Domínguez-Soto

×

Figure 2

GSK3β inhibition upregulates MAFB-dependent genes and the expression of the gene sets that define pathogenic macrophage subsets in severe COVID-19.

Options: View larger image (or click on image) Download as PowerPoint
GSK3β inhibition upregulates MAFB-dependent genes and the expression of ...
(A) Schematic representation of the treatment of M-MØ to CHIR99021 (10 μM, CHIR-M-MØ) or DMSO (DMSO M-MØ). (B) GSEA of the MAFB-dependent gene set on the comparison of CHIR-M-MØ and DMSO M-MØ transcriptomes. (C) Overlap between the genes upregulated (|log2FC| > 1; Padj < 0.05) in CHIR-M-MØ (relative to DMSO M-MØ) and MAFB-dependent genes. (D) GSEA summary of gene sets characterizing macrophage subsets identified in severe COVID-19 (39, 48, 49) on the comparison of CHIR-M-MØ and DMSO M-MØ transcriptomes. The source of the original data is indicated. Leading edge analysis of the GSEA of the genes that define the MoAM3, SPP1+, or CD163+/LGMN+ subsets on the ranked comparison of the transcriptomes of CHIR-M-MØ versus DMSO M-MØ is shown in the bottom panel. (E) Relative expression of the indicated MAFB-dependent genes in CHIR-M-MØ and DMSO M-MØ (GSE185872). Mean ± SEM of 3 independent donors are shown, with indication of the Padj. Statistical significance was calculated using the R package DESeq2. (F) Production of soluble factors by CHIR-M-MØ and DMSO M-MØ determined by ELISA. Mean ± SEM of 3 independent donors are shown (*P < 0.05; **P < 0.01). Statistical significance was calculated using paired ratio t test (2 tailed). (G) Relative mRNA levels of specified genes (LGMN, OLFML2B, IL10) in M-MØ after indicated treatments, with mean ± SEM of 3 independent samples and significance (*P < 0.05; **P < 0.01) determined by 1-way ANOVA with Tukey multiple-comparison test. (H) Production of LGMN, CCL18, and IL10 by M-MØ after indicated treatments, as determined by ELISA, with mean ± SEM of 4 independent samples and significance (*P < 0.05; **P < 0.01; ***P < 0.005) calculated by 1-way ANOVA (Tukey multiple-comparison test).

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts